Navigation Links
Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society
Date:8/15/2011

MINNETONKA, Minn., Aug. 15, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of two clinical studies using Uroplasty's Urgent® PC Neuromodulation System are scheduled to be presented at the International Continence Society meeting, August 29-September 2, 2011 in Glasgow, Scotland.  

"These data from on-going clinical studies continue to demonstrate the long-term efficacy of percutaneous tibial nerve stimulation (PTNS) delivered via Urgent PC in the treatment of overactive bladder syndrome," said David Kaysen, President and CEO of Uroplasty.  "The studies build on a growing body of evidence that validates the treatment protocol, usefulness with both young and elderly patients, and the durability of the improvements with continued PTNS therapy."  

ICS Presentations

  • SUmiT Trial Outcomes: Clinical Insights into Percutaneous Tibial Nerve Stimulation, presented by Dr. Peter Sand, NorthShore University Health, Chicago, IL
  • Demonstrated that results are consistent for patients regardless of age
  • Demonstrated that improvement occurs throughout the series of 12 initial treatments, with more improvement occurring during treatments 7 through 12
  • Treatment Interval Frequency of Percutaneous Tibial Nerve Stimulation: 18-Month Results from the STEP Study, presented by Dr. Kenneth Peters, William Beaumont Hospital, Royal Oak, MI
  • Responders to the initial series of 12 treatments treated with regular PTNS therapy, on an average of once per month, sustained their improvements in voiding symptoms and Quality of Life measures throughout 18 months of therapy  

  • About Uroplasty Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.  We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

    Safe HarborThis press release contains forward-looking statements that reflect our best estimates regarding future events that could affect our financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report and on Form 10-K filed with the SEC.  We cannot be certain that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.Company Contact:Investor Relations Contacts:Media Contact:Uroplasty, Inc.

    EVC Group, Inc.

    EVC Group, Inc.David Kaysen, CEO

    Doug Sherk/Jenifer Kirtland

    Chris Gale/ Steve DiMattia(952) 426-6140

    (415) 568-9349

    (646) 201-5431dave.kaysen@uroplasty.com

    dsherk@evcgroup.com

    cgale@evcgroup.comjkirtland@evcgroup.com

    sdimattia@evcgroup.com
    '/>"/>

    SOURCE Uroplasty, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System
    2. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
    3. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
    4. Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
    5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
    10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/10/2017)... , May 10, 2017 CSSi, the global ... the clinical research industry, is proud to announce the ... The new website features both enriched content and a ... and enhances the company,s already well-established position as the ... "After many months of hard work, we ...
    (Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
    (Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
    Breaking Medicine Technology:
    (Date:5/26/2017)... ... 2017 , ... “Cactus Jack: Against All Odds”: the story of Coach Cactus ... Against All Odds” is the creation of published author, Walter Hubbard, a retired wildlife ... Carlisle’s third child Jane. Walter. Walter and Jane have three adult children and ...
    (Date:5/24/2017)... York (PRWEB) , ... May 24, 2017 , ... Dr. ... vascular surgery in New York City. He is known for his distinguished expertise ... in vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and ...
    (Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
    (Date:5/24/2017)... ... May 24, 2017 , ... Dr. Curry Leavitt, a noted ... Periodontal Practice) continuing education (CE) series. As a compassionate and dedicated clinician, Dr. ... attending numerous CE courses each year. His recent course, Course II of HP3, ...
    (Date:5/24/2017)... ... May 24, 2017 , ... If you are thinking of a visit to ... business architecture, October is the perfect time to visit. , Business Architecture Associates is pleased ... carte offering for individuals, as a 4-½ day package for individuals, and as 4-½ day ...
    Breaking Medicine News(10 mins):